{
    "clinical_study": {
        "@rank": "164870", 
        "arm_group": [
            {
                "arm_group_label": "9-14 year old girls, 2-dose (0, 6 months)", 
                "arm_group_type": "Experimental", 
                "description": "V503 administered at 0 and 6 months"
            }, 
            {
                "arm_group_label": "9-14 year old boys, 2-dose (0, 6 months)", 
                "arm_group_type": "Experimental", 
                "description": "V503 administered at 0 and 6 months"
            }, 
            {
                "arm_group_label": "9-14 year old girls + boys, 2-dose (0, 12 months)", 
                "arm_group_type": "Experimental", 
                "description": "V503 administered at 0 and 12 months"
            }, 
            {
                "arm_group_label": "16-26 year old women, 3-dose (0, 2, 6 months)", 
                "arm_group_type": "Active Comparator", 
                "description": "V503 administered at 0, 2 and 6 months"
            }, 
            {
                "arm_group_label": "9-14 year old girls, 3-dose (0, 2, 6 months)", 
                "arm_group_type": "Experimental", 
                "description": "V503 administered at 0, 2 and 6 months"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is a 37-month safety and immunogenicity study conducted in boys and girls 9 to 14\n      years of age and in females 16 to 26 years of age. From this study, the goal is to establish\n      that the investigational 2-dose regimens (0, 6 months and 0, 12 months) studied in boys and\n      girls 9 to 14 years of age are generally safe and immunogenic, with an antibody response\n      that is not inferior to that observed in females 16 to 26 years of age (the core efficacy\n      population, assessed concurrently in this study) who received the standard 3-dose regimen of\n      V503."
        }, 
        "brief_title": "A Phase III Study of a 2-dose Regimen of a Multivalent Human Papillomavirus (HPV) Vaccine (V503), Administered to 9 to 14 Year-olds and Compared to Young Women, 16 to 26 Years Old (V503-010)", 
        "completion_date": {
            "#text": "August 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Human Papillomavirus Infection", 
        "condition_browse": {
            "mesh_term": [
                "Warts", 
                "Papillomavirus Infections"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        All Participants:\n\n        -Judged to be in good physical health on the basis of medical history, physical\n        examination and laboratory results\n\n        Boys and Girls 9 to 14 Years:\n\n        -Must not have had coitarche and does not plan on becoming sexually active during the\n        vaccination period\n\n        Women 16 to 26 Years:\n\n          -  Has never had a Pap test or only had normal Pap test results\n\n          -  A lifetime history of 0 to 4 male and/or female sexual partners\n\n        Exclusion Criteria:\n\n        All Participants:\n\n          -  Known allergy to any vaccine component\n\n          -  History of severe allergic reaction that required medical intervention\n\n          -  Thrombocytopenia or any coagulation disorder\n\n          -  Females only: participant is pregnant or expecting to donate eggs during day 1\n             through month 7\n\n          -  Currently immunocompromised, or been diagnosed with immunodeficiency\n\n          -  Had a splenectomy\n\n          -  Receiving or has received immunosuppressive therapies within the last year\n\n          -  Received any immunoglobulin product or blood-derived product within 3 months\n\n          -  Received a marketed HPV vaccine or has participated in an HPV clinical trial"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "26 Years", 
            "minimum_age": "9 Years"
        }, 
        "enrollment": {
            "#text": "1500", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01984697", 
            "org_study_id": "V503-010", 
            "secondary_id": "2013-001314-15"
        }, 
        "intervention": {
            "arm_group_label": [
                "9-14 year old girls, 2-dose (0, 6 months)", 
                "9-14 year old boys, 2-dose (0, 6 months)", 
                "9-14 year old girls + boys, 2-dose (0, 12 months)", 
                "16-26 year old women, 3-dose (0, 2, 6 months)", 
                "9-14 year old girls, 3-dose (0, 2, 6 months)"
            ], 
            "description": "V503, a 9-valent HPV (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) administered as a 0.5-mL intramuscular injection", 
            "intervention_name": "V503 (9-valent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) vaccine)", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 8, 2014", 
        "number_of_arms": "5", 
        "official_title": "A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of a 2-dose Regimen of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, Administered in Preadolescents and Adolescents (9 to 14 Year Olds) With a Comparison to Young Women (16 to 26 Year Olds)", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Canada: Health Canada", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "HPV-9 Competitive Luminex Immunoassay (cLIA) Geometric Mean Titers (GMTs) to HPV types at 4 weeks post last dose", 
            "safety_issue": "No", 
            "time_frame": "4 weeks following the last dose of vaccine"
        }, 
        "removed_countries": {
            "country": [
                "United States", 
                "Canada", 
                "Chile", 
                "Colombia", 
                "Czech Republic", 
                "Israel", 
                "Korea, Republic of", 
                "Malaysia", 
                "Norway", 
                "South Africa", 
                "Denmark", 
                "Spain", 
                "Turkey", 
                "Thailand"
            ]
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01984697"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Percentage of participants with HPV-9 cLIA seroconversion to HPV types at 4 weeks post last dose", 
            "safety_issue": "No", 
            "time_frame": "4 weeks following the last dose of vaccine"
        }, 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}